Company Filing History:
1 out of 2 
1 out of 111 Years Active: 1996-2001
Title: The Innovations of Christopher Cheadle
Introduction
Christopher Cheadle is an accomplished inventor based in West Chester, PA. He holds two patents that contribute significantly to the field of biomedical research. His work focuses on therapeutic methods and the development of monoclonal antibodies.
Latest Patents
Cheadle's latest patents include "Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same." This patent discloses hybridoma cell lines that produce monoclonal antibodies capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors. The therapeutic uses of these antibodies, both alone and in combination with anti-neoplastic agents, are also detailed. Another notable patent is "Expression cloning of c-src SH3-domain binding proteins." This invention provides a unique SH3 binding domain core motif and cDNA clones encoding proteins that interact with the SH3 domain of c-src. It also includes methods for identifying SH3-binding proteins and elucidating the sequences that mediate binding.
Career Highlights
Throughout his career, Cheadle has worked with notable companies such as Rhone-Poulenc Rorer International Holdings, Inc. and Rhone-Poulenc Rorer Pharmaceuticals Inc. His contributions to these organizations have been instrumental in advancing their research initiatives.
Collaborations
Cheadle has collaborated with esteemed colleagues, including George A. Ricca and Victoria J. South. These partnerships have fostered innovation and have led to significant advancements in their respective fields.
Conclusion
Christopher Cheadle's work in the field of biomedical research showcases his dedication to innovation and invention. His patents reflect a commitment to developing therapeutic methods that can potentially improve patient outcomes.